NATIONAL INSTITUTES OF HEALTH
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Mechanisms of Diabetes Control After Weight Loss Surgery
- Conditions
- Gastric Bypass SurgeryObesity
- Interventions
- Other: Diet induced weight lossProcedure: gastric bypass surgery
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2018-03-09
- Target Recruit Count
- 20
- Registration Number
- NCT00571220
- Locations
- πΊπΈ
St Luke's Roosevelt Hospital Center, New York, New York, United States
Improving Health Habits in Impoverished Populations
- Conditions
- DiabetesChronic Diseases
- Interventions
- Behavioral: Fighting Cancer with AdviceBehavioral: Self-Care Stimulating Disease Prevention Program
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2011-06-07
- Target Recruit Count
- 100
- Registration Number
- NCT00569595
- Locations
- πΊπΈ
UCLA Department of Family Medicine, Los Angeles, California, United States
πΊπΈQueenscare Family Clinics, Los Angeles, California, United States
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
- Conditions
- Colorectal Neuroendocrine Tumor G1Gastric Neuroendocrine Tumor G1Neuroendocrine NeoplasmNeuroendocrine TumorNeuroendocrine Tumor G2
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 427
- Registration Number
- NCT00569127
- Locations
- πΊπΈ
Providence Hospital, Mobile, Alabama, United States
πΊπΈFairbanks Memorial Hospital, Fairbanks, Alaska, United States
πΊπΈMercy Hospital Fort Smith, Fort Smith, Arkansas, United States
1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00567931
- Locations
- πΊπΈ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
πΊπΈVirginia Commonwealth University, Richmond, Virginia, United States
Phase II Study of Vandetanib in Individuals With Kidney Cancer
- Conditions
- Renal CancerVon Hippel Lindau
- Interventions
- Drug: ZACTIMA (Vandetanib) (ZD6474)
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00566995
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
The Effect of Ethanol on Overnight Glucose Regulation in Type 2
- Conditions
- Type 2 Diabetes, Insulin Requiring
- Interventions
- Other: soda waterOther: IV ethanolOther: oral ethanol, overnight
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2014-09-25
- Target Recruit Count
- 24
- Registration Number
- NCT00566592
- Locations
- πΊπΈ
University of New Mexico Clincal and Translational Science Center, Albuquerque, New Mexico, United States
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Fallopian Tube Mucinous AdenocarcinomaOvarian Clear Cell AdenocarcinofibromaOvarian Serous AdenocarcinomaPrimary Peritoneal Undifferentiated CarcinomaUndifferentiated CarcinomaClear Cell AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaOvarian Brenner TumorOvarian Clear Cell AdenocarcinomaOvarian Transitional Cell Carcinoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life Assessment
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1052
- Registration Number
- NCT00565851
- Locations
- πΊπΈ
John Muir Medical Center-Concord, Concord, California, United States
πΊπΈUCHealth University of Colorado Hospital, Aurora, Colorado, United States
πΊπΈBanner North Colorado Medical Center, Greeley, Colorado, United States
Studying a Quality of Life Questionnaire in Patients With Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 350
- Registration Number
- NCT00564694
- Locations
- π«π·
Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France
π©πͺCharite University Medical Center of Berlin, Berlin, Germany
π©πͺKlinikum der Universitaet Regensburg, Regensburg, Germany
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
- Conditions
- Recurrent Skin CancerSquamous Cell Carcinoma of the SkinStage 0 Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic Leukemia
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 7
- Registration Number
- NCT00563290
- Locations
- πΊπΈ
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
πΊπΈOhio State University Medical Center, Columbus, Ohio, United States
πΊπΈM D Anderson Cancer Center, Houston, Texas, United States
Eat Well Live Well Nutrition Program
- Conditions
- Diabetes or Diabetes Prevention
- Interventions
- Behavioral: Eat Well Live Well Nutrition Program
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2010-01-15
- Target Recruit Count
- 398
- Registration Number
- NCT00561158